Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154119 | 0.93 | HTR6 (0.39) | HTR6MMP2MMP9DRD1 | |
| SCHEMBL2153210 | 0.92 | HTR6 (0.39) | HTR6MMP2MMP9 | |
| SCHEMBL14717648 | 0.90 | HTR6 (0.40) | HTR6DRD1HTR1AHTR2AHTR7 | |
| SCHEMBL14718321 | 0.89 | HTR6 (0.39) | HTR6DRD1HTR1AHTR2AHTR7 | |
| SCHEMBL2154054 | 0.89 | HTR6 (0.48) | HTR6MMP2MMP9 | |
| SCHEMBL14718397 | 0.88 | AKR1A1 (0.34) | HTR6 | |
| SCHEMBL14718343 | 0.86 | HTR6 (0.45) | HTR6DRD1HTR1AHTR2AHTR7 | |
| SCHEMBL2153305 | 0.86 | HTR6 (0.36) | HTR6DRD1HTR1AHTR2AHTR7 | |
| SCHEMBL2153955 | 0.86 | HTR6 (0.36) | HTR6DRD1HTR1AHTR2AHTR7 | |
| SCHEMBL2153524 | 0.85 | HTR6 (0.51) | HTR6MMP2MMP9DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519527-B1 | THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-12-18 | — | — | EP | claimed |
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-02-28 | — | — | US | claimed |
| US-9365584-B2 | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof | POXEL (FR) | 2016-06-14 | — | — | US | disclosed |
| EP-2519527-B1 | THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | PRKAB1, PRKAG1, PRKAB2 | HTR6 2378/4885MMP2 4000/4885MMP9 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.